UREGIT
Active material: Ethacrynic acid
When ATH: C03CC01
CCF: Diuretic
When CSF: 01.08.01.01
Manufacturer: EGIS PHARMACEUTICALS Plc (Hungary)
Pharmaceutical form, composition and packaging
Pills white or grayish white color, round, flat, chamfered, with Valium on one party and chasing “UREGYT” on the other side, with little or no odor.
| 1 tab. | |
| ethacrynic acid | 50 mg |
Excipients: gelatin, lactose monohydrate, magnesium stearate, potato starch, talc.
10 PC. – blisters (2) – packs cardboard.
DESCRIPTION OF ACTIVE SUBSTANCES
Pharmacological action
“Loop” diuretic, dichlorophenoxyacetic acid derivative. Has expressed diuretic effect, increases the excretion of urine sodium ions, Chlorine, Potassium, magnesium and calcium. The mechanism of action is related to the oppression of reabsorption of ions and water in thick segment of ascending Department hinges genle, as well as in proximal tubular izvitom. Does not affect the activity carboangidraza, does not increase the secretion of bicarbonate. Reduces ad system. After a single intake of dioreticeski effect begins in 20-40 m, reaches through 1-2 hours and lasts 6-9 no.
Pharmacokinetics
After intake of ethacrynic acid is rapidly absorbed from the digestive tract. Plasma protein binding is high. It is metabolized in the liver. T1/2 is 30-60 m. Return with urine and through the intestine, unedited, and in the form of metabolites.
Testimony
Edematous syndrome of various genesis: chronic heart failure IIB-III degree, cirrhosis of the liver (Portal hypertension syndrome), nephrotic syndrome; pulmonary edema, cephaledema; arterial hypertension (in a combination therapy).
Dosage regimen
When administered to adults, the initial dose is 50 mg, frequency of administration – 1-2 times / day. Diagram of maintenance therapy is individually. The maximum dose is 200 mg / day.
For children initial dose of 25 mg.
The on/in a single dose for adults is 0.5-1 mg / kg.
Side effect
From the digestive system: anorexia, nausea, vomiting, stomach ache, diarrhea; rarely – acute pancreatitis.
From the water-electrolyte balance: chloropenia, kaliopenia, giponatriemiya, gipomagniemiya, hypocalcemia, degidratatsiya, metabolic alkalosis.
Cardio-vascular system: in some cases – orthostatic hypotension, tachycardia, abnormal heart rhythm.
Other: Valium actions, dizziness, headache, muscular weakness.
Contraindications
Anuria, acute glomerulonephritis, expressed violations vodno-elektrolitnogo balance and KHR, pechenochnaya coma, Children up to age 2 years, hypersensitivity to etakrinova acid, severe renal insufficiency, prekomatosnye status, gout in history, hyperuricemia, hearing disorder, myocardial infarction, a history of pancreatitis, diabetes, pregnancy, lactation, hypersensitivity to etakrinova acid.
Pregnancy and lactation
Etakrinova acid application is contraindicated in pregnancy and lactation (breast-feeding).
Cautions
Be wary appointed during therapy drugs naperstanki, in certain types of diarrhea, chronic heart failure, cirrhosis, asci, ventricular arrhythmia in history, nephropathy with gipokaliemiei, giperal'dosteronizme normal renal function, Systemic Lupus Erythematosus in history.
During treatment, it is necessary to conduct regular monitoring of electrolytes in the blood plasma, eat foods rich in potassium, If necessary, designate drugs potassium simultaneously.
With the development of diarrhea, or symptoms of dehydration treatment should be discontinued.
It is not recommended to install/children.
Effects on ability to drive vehicles and management mechanisms
In the initial, individually determined period of treatment, contraindicated driving vehicles and engaging in other potentially hazardous activities, requiring quick emotional reactions. Further the degree of limitation depends on the portability of patient etakrinova acid.
Drug Interactions
Together with the use of antibiotics group aminoglikozidov (incl. with genthamitinom, kanamycin, Streptomycin, neomycin) may increase as a result of ototoksicski additive effect (especially in patients with renal insufficiency), increased risk of nefrotoksicski action.
Together with the use of beta-agonists (incl. with fenoterolom, terbutalinom, salbutamol) Perhaps increased hypokalemia.
While the use of beta-blockers, gidralazinom, verapamil, nifedipine, captopril, clonidine, methyldopa, octadine, prazosin, rezerpinom amplified antihypertensive.
If you are applying with ganglioblokatorami possible ortostatical gipotenzia.
Together with the application kalisberegatmi dioretikami amplified dioreticeski effect, decreases gipokaliemia and gipomagniemia.
Together with the use of CORTICOSTEROIDS is enhanced by hypokalemia, diminishes antihypertensive activity etakrinova acid.
Together with the use of NSAIDS may decrease effects etakrinova acid.
With simultaneous use of medicines, intensively linking blood plasma proteins (warfarin, clofibrate) Perhaps increased dioreticski effect and hypokalemia, tk. as a result of competition for binding protein with the plasma concentration of free (active) etakrinova acid increases.
If you are applying with laxatives, expressed possible dehydration, reduction of sodium in the body, potassium and magnesium.
If you are applying with tools, causing acidification of the urine, may increase effects etakrinova acid.
While applying astemizola increases the risk of arrhythmia.
Together with the use of Vancomycin may increase the UTO- and nephrotoxicity.
Together with the use of cholesterol can increase the risk of nefrotoksicski cephalosporin.
If you are applying with tetratziklinami concentrations of urea in the blood, that is especially dangerous in renal failure.
If you are applying with cizapridom may increase hypokalemia.
